C-CZZNAI-enabled drug discovery, core aging mechanisms, small molecules/biologics/cell therapies
0-100 chain-logic scale · 15 dimensions · scored on public evidence
There are already more people in Britain over 65 than under 16. Average life expectancy is predicted to rise by 10 years in the next two decades. And scientists at Harvard have begun clinical trials to reverse vision loss by reprogramming old cells back to being young. The longevity revolution isn't coming. It's already here. This panel brings together billionaire life sciences investor Jim Mellon, co-founder of Juvenescence, Professor Georgina Ellison Hughes of King's College London, Harley Street GP and aging medicine expert Dr. Angela Rai, and Duncan Garrard, CEO of Goldman Sachs-backed Riverstone Living — to unpick what living longer actually means, and what you should be doing about it right now. In this conversation: — Why your biological age matters more than your chronological age — and how to test it — The drugs targeting "zombie cells" that refuse to die — and what they could do for your health span — How scientists are reprogramming old cells to be young again — The four
Inclusive Innovation: Addressing the Underrepresentation of Older People in Clinical Trials - Longevity Week 2024 This insightful workshop was organised by the Ageing, Business, and Society Special Interest Group (ABS SIG) of the British Society of Gerontology during Longevity Week 2024. The session addressed the significant underrepresentation of older adults in clinical research—a gap that limits the applicability of treatments and hinders the development of safe and effective therapies for all age groups. Speakers Included: • Dr. Declan Doogan – Co-founder of Juvenescence • Dr. Emma Harvey – Vice President, Faculty of Pharmaceutical Medicine • Jeremy Taylor OBE – Director for Public Voice, National Institute for Health and Care Research • Professor David Wilkinson – Founder and Director, Parkinson's Centre for Integrated Therapy • Hannah Thomson – Founder and CEO, The Joy Club The workshop featured thought-provoking discussions on the challenges and opportunities for increasing th
Life-changing advances in medicine are happening right now. And at the forefront of that progress are anti-aging drugs. Jim Mellon and his team at Juvenescence are right at the heart of these developments in the field of human longevity. Juvenescence asks the question: 'What would you do with more life in your lifetime?' Right now, we could all provide a hypothetical answer. In the next 10 years, those answers could start becoming reality. #science #antiaging #juvenescence #longevity
Exciting News! We are thrilled to announce that Jim Mellon will be speaking at this year's Longevity Summit Dublin, offering insights into the latest frontiers in longevity, biotech, and rejuvenation. Don't miss this chance to explore cutting-edge perspectives from a leader in the field! Tickets available here https://longevitysummitdublin.com/ Jim Mellon is a prominent figure in the field of longevity and investment. His innovative approach views longevity not only as a health issue but also as a strategic financial decision that could reshape the future. As a co-founder of Juvenescence®, he actively participates in activities related to advancing longevity research and innovation. His contributions to the field have been recognized through his involvement in events and platforms dedicated to discussing the intersection of longevity, biotech, and rejuvenation #JimMellon #LongevitySummitDublin #Biotech #Rejuvenation #InvestmentOpportunity #ScientificInnovation #FutureofHealthcare#J
Dr Declan Doogan, MD, a co-founder of Juvenescence, was driven to start the company because he believes we all can do better in managing health as we get older. Dr Doogan has more 30 years' experience in the global pharmaceutical industry. He was Head of Worldwide Drug Development at Pfizer, working in the US, UK and Japan. Dr Doogan was also head of R&D at Amarin where he helped raise $100m to fund the reorganization and portfolio realignment leading to the NDA approval for Vascepa (icosapent ethyl) for elevated triglycerides. During his career, Declan has engaged in activities to promote excellence in pharmaceutical medicine and sits on the boards of several biotechnology companies and multiple pharmaceutical companies. He is Chairman and co-founder of Biohaven Pharmaceuticals, Portage Biotech, and PHPrecisionmed. Dr Doogan graduated Medicine from Glasgow University, is a Fellow of the Royal College of Physicians and Surgeons of Glasgow, and holds an honorary degree of DSc from th
In this episode John Reynolds talks to visionary entrepreneur, investor, philanthropist and top 10 Times Rich list billionaire Jim Mellon. Jim is also a best selling author who famously predicted the 2008 Credit crunch in one of his books ‘Wake Up’. Jim is the founder of biotech company Juvenescence, inspired by the possibilities and advances being made in the area of longevity, focussing on helping people live healthier in old age. His pioneering work with Juvenescence means that in the next 30 years, life expectancy from birth is predicted to rise to between 110 and 120. Jim discusses Traditional farming as we know it and how it will be completely revolutionised with dairy and animal farming set to be entirely obsolete in the near future. Why though? Jim gives an insight into his goals of protecting the environment, promoting human and animal welfare, and generating financial returns. Proudly sponsored by the Jorja Emerson Centre
Declan Doogan, Chief Medical Officer of Juvenescence interviews world renowned scientist and centenarian James Lovelock on his tactics for a long life. James Lovelock is also The Longevity Forum Person of the Year for 2021. While there is no secret recipe for 100 years, James Lovelock discusses the importance of staying active and mentally challenging yourself. As the proposer of the Gaia principle, James joins Declan in considering the environmental factors that are harming society as well as how these problems can affect healthy lifespans. https://www.thelongevityforum.com
Dr Declan Doogan of Juvenescence presents the Longevity Person of the Year Award to scientist and centenarian James Lovelock.
Declan Doogan, Chief Medical Officer of Juvenescence interviews Professor Norman Lazarus, the author of The Lazarus Strategy: How to Age Well and Wisely on the importance of exercise for longer lives. We analyse not just genetics but “diseases of exercise deficiencies.” You need to change your lifestyle now and there needs to be a focus on physical exercise. Exercise is intrinsic to the human species so its crucial to find something you enjoy otherwise your physical activity will be a struggle. Always compliment your exercise with weight resistance and Norman offers guidance on proper muscle development. Declan and Norman end their conversation on how the pandemic has brought awareness to exercise and health resilience to our institutions and government. Podcast channels: Apple https://tinyurl.com/ukdru7sw Google https://tinyurl.com/52bep6ck Spotify https://spoti.fi/3wftFbR
Welcome to another episode of SALT Talks with host Anthony Scaramucci and guest Jim Mellon, the co-founder and Chairman of Juvenescence. Juvenescence was inspired by the possibilities and advances being made in the area of longevity. He travelled across the world speaking to leading scientists and researchers and from those conversations, he wrote the book, Juvenescence. That book and his partnership with Greg Bailey and Declan Doogan led to the concept and rare opportunity to reinvent human aging. Jim is an international investor with interests in several industries. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focus
Prof Norman Lazarus, Professor at the Centre for Human and Applied Physiological Sciences at Kings College London and Declan Doogan, Chief Medical Officer of Juvenescence chat about the resilient lifestyle. A healthy lifestyle isn't just making a few good decisions but is about finding something that resonates with you. Ageing doesn't mean that taking up a new hobby such as swimming is out of reach but can be a new challenge. Prof Norman Lazarus discusses the many options one can take for a long, active life. https://thelongevityforum.com
Jim Mellon, Juvenescence, UK, presents at the 2020 Aging Research and Drug Discovery conference. About the Aging Research and Drug Discovery meeting: According to the United Nations, the proportion of people aged over 65 now outnumber children younger than 5. The enormous growth in the elderly population is posing a socioeconomic challenge to societies worldwide, and necessitates new sweeping interventions for age-associated diseases. This year we have an incredibly exciting program with global thought-leaders sharing their latest insights into aging and how we target aging process ensuring everyone lives a healthier and longer life. Welcome to the 7th Aging Research and Drug Discovery Meeting. Read more on: www.agingpharma.org
Join Jim Mellon, Chairman & Co-Founder, Juvenescence to find out more. The Longevity Leaders channel features sessions from the Longevity Leaders Congress, where our mission is to advance innovations that will extend human #healthspan and enable financial, physical and mental #wellness in later life. Sessions feature influential leaders from the worlds of ageing science, consumer products, finance, technology and investment. The events sit at the centre of a global ecosystem, connecting people, knowledge and investment to address the impact of how we age and how we cater for an ageing society. Follow Longevity Leaders on Twitter: https://twitter.com/longevityleader Like Longevity Leaders on Facebook: https://www.facebook.com/LongevityLeaders/ Subscribe to our channel for more longevity videos. Visit us at www.longevityleaders.com
Jim Mellon, author of Juvenescence delivers his keynote on the science of living longer at the inaugural Longevity Forum 2018. https://thelongevityforum.com As science catches up with the human aspirations of living longer, a new approach to public health is urgently required. Our Juvenescence agenda advocates a new model for both health promotion and disease prevention which can support healthy longevity, increase life expectancy, improve overall productivity and ensure that healthcare spend is focused on preventing the diseases of ageing rather than on curing them. Jim Mellon is a British entrepreneur and investor with a wide range of interests. Through his private investment company, Burnbrae Group, he has substantial real estate holdings in Germany and the Isle of Man, as well as holdings in private and public companies. Jim’s investment philosophy is underpinned by his ability to recognise emerging trends that give rise to new industries or major shifts in markets. These tre
Jim Mellon, Co-Founder of The Longevity Forum, discusses the mission of the Forum, scientific progress and its impact on the longevity economy. https://thelongevityforum.com Jim Mellon is a British entrepreneur and investor with a wide range of interests. Through his private investment company, Burnbrae Group, he has substantial real estate holdings in Germany and the Isle of Man, as well as holdings in private and public companies. Jim’s investment philosophy is underpinned by his ability to recognise emerging trends that give rise to new industries or major shifts in markets. These trends which often turn into “money fountains” have included the financial crisis of 2008-2009, as foreseen in first book Jim co-authored entitled Wake Up!, and subsequently in the new science and technologies detailed in Cracking the Code and Fast Forward. Jim’s next money fountain is the field of longevity, and is outlined in the book Juvenescence. For decades, scientist have quietly been working
Health in the Age of Longevity Declan Doogan, CMO at Juvenescence speaking at Master Investor’s Investing in the Age of Longevity 2019 event. Declan discusses health in the age of longevity. Master Investor is an investment media and events company that delivers independent, financial commentary and analysis to UK private investors and traders through events, magazines, news, blogs, podcasts and daily/weekly newsletters. Read our latest magazine at www.masterinvestor.co.uk/magazine Book a free ticket (use code MIYT) to attend the annual Master Investor Show (28th March 2020): https://masterinvestorshow-2020.reg.buzz Keep in touch: Newsletter | https://masterinvestor.co.uk/subscribe Twitter | https://twitter.com/masterinvestor Facebook | https://facebook.com/masterinvestor LinkedIn | https://www.linkedin.com/company/masterinvestor
How many years do you think you’ll spend in retirement: 20…maybe 30? Jim Mellon, author of a book called “Juvenescence: Investing in the Age of Longevity,” tells Bloomberg that we’re about to see more major advancements in the average lifespan… So, how do we build a nest egg that’ll pay for that many years of retirement? Learn more: https://clearincomeforlife.com/ Facebook: https://www.facebook.com/ClearIncomeS... LinkedIn: https://www.linkedin.com/company/clea... Twitter: https://twitter.com/clear_income
Interview with hugely successful investor Jim Mellon at the Undoing Aging conference in Berlin 2019! We cover reasons why it's a good time to invest in Anti-Aging and rejuvenation biotechnology today, the ethical reasons why we should, and effective advocacy: i.e. what one would say to a billionaire to convince them that investing in longevity medicine is a good thing to do now. Jim raised over $150 Million for his venture Juvenescence recently! Bio: Jim Mellon is an investor with an interest in several industries. After studying PPE at Oxford, Jim worked in Asia and in the US for two fund management companies, GT Management and Thornton & Co, before establishing his own business in 1991. This business is now known by two names - Charlemagne Capital, recently acquired, and Regent Pacific Group, listed in Hong Kong. Jim's private investment company, The Burnbrae Group, is a substantial landlord in Germany and the Isle of Man, and owns the group Sleepwell Hotels. Jim is chairman and maj
Jim Mellon is an Investor and co-author of the book "Juvenescence: Investing in the Age of Longevity" https://www.juvenescence-book.com/ https://en.wikipedia.org/wiki/Jim_Mellon
James Strole, Director of the Coalition for Radical Life Extension, organizers of RAADfest, and Jim Mellon, Juvenescence Chairman, British entrepreneur, philanthropist and investor with interests in several industries, discusses the importance of investing in longevity and attending RAADfest 2018. --Learn more and register for RAADfest 2018 today: http://www.raadfest.com/ -Learn more about Juvenescence: https://www.juvenescence.ltd/ -Learn more about the Coalition: http://www.rlecoalition.com/ The Coalition for Radical Life Extension is a non-profit organization.
My guest today on Stuff That Interests Me is one of Britain's most successful investors, Jim Mellon. You're going to live till your 120. Jim explains why - a combination of new drugs, technologies and lifestyles. What are you going to do with all your time? The next great investment trend will be around the fact that we are all going to love a lot longer. Find out more in the this fascinating interview. Juvenescence - Investing in the Age of Longevity is available from all good bookstores and at https://www.juvenescence-book.com/
Jim Mellon and Al Chalabi have written a new book "Juvenescence: Investing in the Age of Longevity" in which they alert readers to the amazing science of Juvenescence, to the prospect of living much longer than most people expect, and also to the ways in which we can prosper as investors in this new era of longevity. In this video, Jim discusses the book's content and why you should read it. Find out more and order online at www.juvenescence-book.com.
Investing in the Age of Longevity 2023 – Discussion Panel Longev… Master Investors Home Episodes Follow Spotify Apple Podcasts Youtube Music Follow Spotify Apple Podcasts Youtube Music Dec. 1, 2023 Investing in the Age of Longevity 2023 – Discussion Panel Longevity Now Show Notes Dr Richard Marshall CBE, CEO at Juvenescence, Bill Kapp, Co-founder and CEO at Fountain Life, and Jörg Rieker, Founding Partner at Maximon, join Phil Newman, Editor-in-Chief at Longevity.Technology, for a panel discussion at Investing in the Age of Longevity 2023. In their chat, participants present the business model … ter Investor Magazine Editor-in-Chief James Faulkner gets to pick the brains of fund managers, CEOs, big shot investors and various other luminaries from the investing world, in order to get you - the private investor - up to speed with all the latest themes in what is a very fast-moving and exciting industry. Episodes © 2026 Master Investors Powered by Podpage + Blubrry
UNDERSTANDING (AND TREATING) A... — The Life Sci Fantastic — Apple Podcasts Поиск Главная Новое Топ-чарты Поиск 17 октября 2025 г. 24 мин. UNDERSTANDING (AND TREATING) AGING The Life Sci Fantastic Воспроизвести Across the world, people can now expect to live longer. These advances are thanks to better sanitation, vaccination, access to food and healthcare. But aging inevitably involves decline in many of our biological functions, making people more susceptible to disease. What - if anything - can be done to address the underlying mechanisms of aging to both prevent and treat illness? Can aging
Our Director of IR, Yehudah Nevies, presenting at Singapore Week of Innovation & Technology - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Our Director of IR, Yehudah Nevies, presenting at Singapore Week of Innovation & Technology Juv on the Road Our Director of IR, Yehudah Nevies, presenting at Singapore Week of Innovation & Technology October 31, 2025 An incredible week in Singapore 🇸🇬 – grateful to HSBC Innovation Banking , Christina Lee & Kerri L. for the opportunity to present Juvenescence® during the buzzing Singapore Week of Innova
Antoxerene Closes $10 Million Deal with Juvenescence to Develop Small Molecule Drugs for Diseases of Aging Skip to content Services Protein Services Protein Expression & Purification Services Adeno-Associated Virus (AAV) Structural Biology Services X-Ray Crystallography Services Biophysical Assays Surface Plasmon Resonance Services Biacore Assay Services Circular Dichroism (CD) Assay Services nanoDSF Assay Services Bio-layer Interferometry Services Isothermal Titration Calorimetry Plate-Based Assay Services View All Protein Services Pharmacology Services Drug Discovery Services Drug Devel
Master Investor 2022: Our CEO, Dr. Greg Bailey, presents Juvenescence - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Master Investor 2022: Our CEO, Dr. Greg Bailey, presents Juvenescence In the News Master Investor 2022: Our CEO, Dr. Greg Bailey, presents Juvenescence February 15, 2023 The investment community is chasing a longer, healthier life like the rest of us. Dr. Greg Bailey , successful investor and CEO/co-founder of Juvenescence, delivers an overview of the company’s areas of focus: cell regeneration (organ regrowth), addressing aging of the immune system
Juvenescence appoints Eileen Jennings-Brown as Chief Technology Officer and strengthens presence in UAE with new partnership and facilities with Masdar City Something went wrong Skip to navigation Skip to main content Skip to right column Yahoo Finance News Finance Sport More News Today's news World UK Weather Politics Science & Tech Lifestyle Health & Wellness Relationships Parenting Entertainment TV Reality TV Movies Celebrity Music Finance My portfolio Watchlists Markets News Screeners Industries Crypto Bank of England Property Top stocks Work and management Brexit Sport Premier Lea … onverter Crypto Stocks: Losers Screeners Saved Screeners Equity Screener Mutual Fund Screener ETF Screener Features Behind The Brand Work & Management ... UK markets closed UK UK US Markets Europe Markets Asia Markets Cryptocurrencies Rates Commodities Currencies UK markets closed FTSE 100 10,373.51 +34.56 +0.33% GBP/USD 1.3470 +0.0008 +0.06% GBP/EUR 1.1574 +0.0012 +0.10% FTSE 250 23,378.36 +132.58 +0.57% AIM 818.32 -0.92 -0.11% GOLD FUTURES 4,516.60 +10.30 +0.23% ADVERTI
Juvenescence Closes Seed Round With Participation From Seasoned Biotech Investors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cance … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Juvenescence Closes Seed Round With Participation From Seasoned Biotech Investors January 8, 2018 | 3 min read Twitter LinkedIn Facebook Email Print Juvenescence announced that it has closed its seed funding round, raising US $12.3 million. Jan. 8, 2018 17:45 UTC TORTOLA, British Virgin Islands--( BUSINESS WIRE )-- Juve … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Juvenescence Closes $100 Million Series B Round, Plans Follow on and Incremental Investments in Longevity Drug Development - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busine … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Deals Juvenescence Closes $100 Million Series B Round, Plans Follow on and Incremental Investments in Longevity Drug Development August 19, 2019 | 2 min read Twitter LinkedIn Facebook Email Print Juvenescence is pleased to announce the successful closure of its $100 million Series B round, including a … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tre … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Serina Therapeutics Congratulates Juvenescence Ltd. on $150M Series B Funding and Strategic Partnership with M42 June 17, 2025 | 4 min read Twitter LinkedIn Facebook Email Print HUNTSVILLE, June 17, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotec … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
JUVENESCENCE Appoints Dr Richard Marshall CBE as CEO - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business JUVENESCENCE Appoints Dr Richard Marshall CBE as CEO January 16, 2023 | 3 min read Twitter LinkedIn Facebook Email Print Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Most recently, Dr Marshall was Senior Vice-President, Global Head of Development, … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Juvenescence raises $100M to fund longevity assets to early readouts | Fierce Biotech Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events Industry Events Webinars Podc … ce Life Sciences Events Advertise About Us Biotech Juvenescence raises $100M to fund longevity assets to early readouts By Nick Paul Taylor Aug 19, 2019 7:30am aging anti-aging drugs diseases of aging Longevity --> Juvenescence has raised $100 million (€90 million) to advance multiple anti-aging programs. The U.K. company, which was co-founded by Jim Mellon, has reeled in $165 million over 18 months to establish itself at the forefront of the nascent longevity sector. After s
Juvenescence Closes First Tranche of Series B Enabling Further Growth and Development - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy C … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Juvenescence Closes First Tranche of Series B Enabling Further Growth and Development January 16, 2019 | 2 min read Twitter LinkedIn Facebook Email Print Juvenescence Ltd, a biopharmaceutical company focused on modifying ageing and age-related disease, is pleased to announce the close of the first tranche of its Series … rstanding of the biology of ageing and has matured such that now is the time to apply cutting-edge techniques of drug discovery and development to develop therapeutics with the possibility of slowing, halting, or potentially reversing elements of ageing. View source version on businesswire.com: https://www.businesswire.com/news/home/20190116005268/en/ Contacts Juvenescence Ltd Chris Shilling [email protected] +44 7721 061115 Source: Juvenescence Limited View this … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Insilico Medicine and Juvenescence Announce First Drug Candidate for Their Joint Venture Company Juvenescence.AI - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Tre … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Insilico Medicine and Juvenescence Announce First Drug Candidate for Their Joint Venture Company Juvenescence.AI February 5, 2018 | 3 min read Twitter LinkedIn Facebook Email Print Juvenescence Limited announces that Juvenescence.AI, its joint venture with Insilico Medicine, Inc. (“Insilico”) … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
NetraMark Corp. and Juvenescence Ltd. launch joint venture, using artificial intelligence to fight aging-related conditions - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business NetraMark Corp. and Juvenescence Ltd. launch joint venture, using artificial intelligence to fight aging-related conditions November 27, 2018 | 3 min read Twitter LinkedIn Facebook Email Print NetraMark Corp. and Juvenescence Ltd. have partnered to form NetraPharma, a joint venture that is us … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
High Calibre Additions to the Juvenescence Team - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business High Calibre Additions to the Juvenescence Team May 21, 2020 | 2 min read Twitter LinkedIn Facebook Email Print Juvenescence Limited, a life sciences company focused on modifying aging and increasing human longevity, is pleased to announce the appointment of Dr. Jean-Christophe Renondin to it … ondin to the Main Board of Juvenescence, representing the State General Reserve Fund (SGRF) of the Sultanate of Oman. Jean-Christophe is a very experienced and respected biotech investor who brings a great deal of both investment and medical knowledge to the Board, as well as a wealth of Middle Eastern contacts, and as such is a very strong addition to the Juvenescence talent bench.” Dr. Greg Bailey, CEO of Juvenescence, said : “We are very fortunate to have been able to attr … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Juvenescence Limited - Artificial Intelligence To Discover Drugs In A Multi-Year Multimillion Dollar Deal - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cel … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Juvenescence Limited - Artificial Intelligence To Discover Drugs In A Multi-Year Multimillion Dollar Deal July 27, 2017 | 5 min read Twitter LinkedIn Facebook Email Print TORTOLA, British Virgin Islands--( BUSINESS WIRE )--Juvenescence Limited (“Juvenescence”) is pleased to announce the launc … Pfizer and current Chairman of Biohaven Pharmaceuticals (NYSE:BHVN), said: “The application of AI techniques to drug discovery has enormous potential and could dramatically alter the way that we discover new drugs and define existing diseases. AI could decrease the cost and increase the speed with which we can bring new medicines to patients." Juvenescence AI has agreed to license selected novel and repurposed compound families from Insilico Medicine on an ongoing basis, with … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Juvenescence Raises $50 Million in Series A Financing - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases Al … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Juvenescence Raises $50 Million in Series A Financing June 11, 2018 | 3 min read Twitter LinkedIn Facebook Email Print Juvenescence Limited, a leader in the development of therapies to slow, halt or potentially reverse aging, has successfully raised $50 million in its Series A financing. DOUGLAS, Isle of Man--( BUSINESS … edicine , a next-generation artificial intelligence company specialising in the application of deep learning to drug discovery and aging research; Juvenescence AI , a joint venture with Insilico Medicine focused on the clinical development of AI-generated compounds; NetraPharma , a joint venture using artificial intelligence to improve clinical trial design; LyGenesis , a company with technology to use a patient’s own lymph nodes as bioreactors to grow functioning ectopic org … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Biomarkers of Aging Consortium - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Biomarkers of Aging Consortium Juv on the Road Biomarkers of Aging Consortium November 13, 2024 I had the best time attending the 2024 Biomarkers of Aging Consortium Conference at Harvard Medical School ! 🧬✨ It was an incredible opportunity to connect with pioneers in aging research, exchange insights, and explore groundbreaking advancements that could redefine the future of healthcare. I presented a poster on behalf of Napa Therapeutics and Juvenescence® that highlights our latest work
Juvenescence acquires AI drug discovery company Ro5 | Juvenescence® posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t
Juvenescence | New York Asset Manager | Altss For Asset Classes Solutions Compare Case Studies Blog Book a demo Home Profiles Juvenescence Asset Manager Updated: May 30, 2026 Juvenescence We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases. Juvenescence We extend healthy lifespan through developing innovative medicines that target core aging mechanisms to not only treat but prevent age-related diseases. Website juvlabs.com Overview Investment focus Team Deals Network General information Firm typ … Preqin Altss vs PitchBook Altss vs FINTRX Altss vs Dakota Company About us Why Submit Data How we Collect Data Press Careers Contribute Submit your firm Submit a deal Submit a fund Follow us
Juvenescence Acquires Ro5 to Integrate AI in Drug Discovery and Development - GeneOnline News Skip to content Advertise Inquiries | About Us | | Events Subscribe Intelligence Menu Toggle Markets & Deals Policy & Regulation Ranking & Reports Founders’ Circle Development to Market Discovery Menu Toggle R&D Frontiers Trials & Approvals CDMO & CRO Activity Public Health Oncology Insights Infection, Immunity & Vaccination Nexus Menu Toggle AI, Tech & Digital Innovation Advanced Biologics & Biosimilars Exosomes & Delivery Precision Medicines Cell, Gene &
Juvenescence Acquires Ro5 to Integrate AI and Machine Learning in Drug Discovery - GeneOnline News Skip to content Advertise Inquiries | About Us | | Events Subscribe Intelligence Menu Toggle Markets & Deals Policy & Regulation Ranking & Reports Founders’ Circle Development to Market Discovery Menu Toggle R&D Frontiers Trials & Approvals CDMO & CRO Activity Public Health Oncology Insights Infection, Immunity & Vaccination Nexus Menu Toggle AI, Tech & Digital Innovation Advanced Biologics & Biosimilars Exosomes & Delivery Precision Medicines Cell, G
Juvenescence's $76M+ to advance CD38, ketone drugs to clinic | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape
Walden / Legacy / Wolf Willow / Chaparral Community Group | Does anyone know how long it takes to be out of the waiting list for the Chaparral School Juvenescence
Instagram Instagram 登录 注册 关闭 绝不错过blackbusinessedmonton的帖子 注册 Instagram 即可持续了解新动态。 注册 登录 标记 jckids_tutoring blackbusinessedmonton 已验证 • 关注 更多选项 blackbusinessedmonton 已验证 51周 🎓🌟 Introducing JC Kids — Juvenescence Candour’s Online Tutoring Platform 🌟🎓 Empowering young learners with impactful, personalized support! 📘 What We Offer Tailored 1:1 Zoom tutoring in Math & English Engaging lessons that foster confidence & academic growth 👶 Age Range Preschoolers through Grade 6 students — building strong foundations early! 📞 Connect with Us 📱 Phone: 825‑523‑6501 ✉️ Email: joanconscience1
Longevity investment bulletin: CohBar, Heartseed, Juvenescence and more Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search HAYA Therapeutics beg … event multiple diseases with a single MRI scan.” SENISCA shortlisted for Nature award Longevity biotech SENISCA announced that it has been shortlisted for the 2022/2023 Nature Spinoff Prize . The prize is awarded yearly by the journal Nature to early-stage university spinoff companies from around the world founded on research in life sciences or physical sciences. The prize aims to give better visibility to companies translating original, high-quality scientific research into … y to rejuvenate aged senescent cells. “Being shortlisted for the Nature Spinoff Prize is an incredible achievement for everyone at SENISCA,” said Professor Lorna Harries, Chief Scientific Officer of SENISCA. “Our inclusion in this prestigious list recognizes the significant potential of our technology to develop new and better treatments for diseases of ageing and make a difference in the lives of patients around the world.” InsideTracker and OURA join forces Digital healthsp … of the enterprises, you create efficiency.” Samsara lands Parkinson’s research grant Autophagy targeting biotech Samsara Therapeutics has received a grant from The Michael J Fox Foundation for Parkinson’s Research to support its research efforts in developing a drug for Parkinson’s disease. Samsara’s lead candidate SAM001 has exhibited the ability to enhance autophagy and mitigate damage to brain cells affected by Parkinson’s Disease and Amyotrophic Lateral Sclerosis (ALS). … addressing the underlying causes of age-related diseases. Hevolution announces grant recipients Longevity non-profit organization Hevolution Foundation announced the latest recipients of the Hevolution Foundation Advancing Geroscience Efforts grants program. First announced in October 2022, the program funds research deemed meritorious and prais
Instagram Instagram Log In Sign Up Close Never miss a post from juvenescencewellness Sign up for Instagram to stay in the loop. Sign up Log in juvenescencewellness • Follow Original audio More options juvenescencewellness 23w Bringing aesthetic beauty to Lake Cowichan — rooted in health from within. At Juvenescence Wellness, we believe the most natural, radiant results begin with supporting the body first. Skin health, energy, and confidence start internally — and when that foundation is strong, aesthetic treatments can be approached thoughtfully and conservatively. Every service, including in
Juvenescence Completes $100 Million Series B Financing Round Subscribe for the newsletter Mobile Navigation Subscribe for the Newsletter Articles Expert Interviews Roundtable Press Releases Videos The Road To Series Market Research Directory Close Discovery Small Molecules Biologics Advanced Therapies Manufacturing Supply Chain Clinical Trials Technologies Financing Juvenescence Completes $100 Million Series B Financing Round C Cynthia A. Challener, Ph.D. Scientific Content Director Pharma's Almanac Aug 27, 2019 PAO-M08-19-NI-035 Financing Juvenescence is on a mission to extend human life … Calico, which is owned by Google and has partnered with AbbVie. Venture capital fund BOLD Capital Partners is looking for others; it announced a $100 million fund targeting companies in the anti-aging field. Nice Insight is the market research division of That’s Nice LLC, the leading marketing agency serving life sciences. Subscribe Explore About Us Nice Insight That's Nice Reach Our Team Contact Us Advertise My Account Login/Sign up Site Privacy Policy Terms And Conditi
Impressions from the January 2019 Juvenescence Gathering – Fight Aging! Home FAQ Fund Research Services Investing Therapies Newsletter Archives Press Room Resources About Fight Aging! Do you want to live a longer life in good health? Simple practices can make some difference, such as exercise or calorie restriction. But over the long haul all that really matters is progress in medicine: building new classes of therapy to repair and reverse the known root causes of aging. The sooner these treatments arrive, the more lives will be saved. Find out how to help » January 14th, 2019 Impr … ber of high net worth individuals, agents for other high net worth individuals, fund partners deploying sizable amounts of capital, successful founders turned angel investors, successful angel investors turned founders - all rubbing shoulders, bumping into one another at the supermarket, and two degrees of separation removed at most. It is through this very connected network that interest in the biotechnologies of rejuvenation has been spreading these past fifteen years, push … Living Longer Read the Fight Aging! FAQ Sign up for the Fight Aging! Newsletter Fund Meaningful Aging Research Services Longevity Industry Consulting How to Start a Longevity Biotech Company The Root Causes of Aging Aging is Caused by Damage Accumulating Cross-Links Buildup of Amyloid Between Cells The Failing Adaptive Immune System The Failing Innate Immune System Declining Lysosomal Function Mitochondrial DNA Damage Nuclear DNA Damage Buildup of Senescent Cells Archives and … Feed RSS Comments Feed Using the Fight Aging! Content Feeds Required Reading A Proposal to Accelerate Progress Calorie Restriction and Longevity Cryonics, the Necessary Backup Plan How to Argue for Longevity Science The Odds of Human Longevity Mutations The Need For Activism and Advocacy Nuanced Opposition to the FDA Potential Gene Therapy Targets Predicting the First Rejuvenation Therapies Self-Experiment to Fight Aging! SENS: Bringing an End to Aging Stem Cells and Regener … ht Aging!. Home | FAQ | Fund Research | Services | Investing | Therapies | Newsletter | Archives | Press Room 
Juvenescence Acquires Ro5 to Integrate AI and Machine Learning in Drug Discovery - GeneOnline News Skip to content Advertise Inquiries | About Us | | Events Subscribe Intelligence Menu Toggle Markets & Deals Policy & Regulation Ranking & Reports Founders’ Circle Development to Market Discovery Menu Toggle R&D Frontiers Trials & Approvals CDMO & CRO Activity Public Health Oncology Insights Infection, Immunity & Vaccination Nexus Menu Toggle AI, Tech & Digital Innovation Advanced Biologics & Biosimilars Exosomes & Delivery Precision Medicines Cell, G
Lifeboat Foundation | Our review of Juvenescence: Investing in the Age of Longevity a new book about rejuvenation biotechnology by Jim Mellon and Al Chalabi
Our co-founder Greg Bailey spoke at the Longevity Investors Conference and discussed the opportunity and responsibility of investing in longevity. Here are the key takeaways: 💡 Aging science is a… | Juvenescence® LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at a
RAADfest 2018 « the Kurzweil Library the Kurzweil Library Tracking breakthroughs in tech, science, and world progress. events Skip to content about + contact newsletter the Kurzweil Library books by Ray Kurzweil writings by Ray Kurzweil Ray Kurzweil lifetime of innovation Ray Kurzweil press + appearances home stories on progress classics a + e resources good books events bulletin board search RAADfest 2018 March 19, 2018 RAADfest is the largest event in the world where practical and cutting-edge methods to reverse human aging are presented by global thought leaders. RAADfest brings toget … ystem aging and more. Bill Faloon — will be introducing therapies you can apply now to possibly reverse your aging. James Strole — Director of the Coalition for Radical Life Extension, will be highlighting the importance of activism for life extension and super longevity, the mindset of an infinite lifespan, and bringing the future to us. Jim Mellon — Entrepreneur and writer of new book Juvenescence that provides the rationale to prioritize funding of the li
Juv on the Road - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Category: Juv on the Road Juv on the Road Eric Verdin, our collaborator in the Buck institute presents data on our compound We were pleased to attend the Longevity Summit 2025 at the Buck Institute for Research on Aging, a vibrant gathering of leaders […] Juv on the Road Presenting at several conferences in the UAE Juvenescence has carried positive momentum into 2026 following a series of invigorating conferences in hashtag#AbuDhabi, where our team joined discussions on shaping the future of has
Longevity: How to Buy Time! | Gregory Bailey, Juvenescence Sign up to get updates from us ... By signing up, you agree to receive email from this podcast. Subscribe Welcome to our new website! The Jess Larsen Show on Innov… Episodes Videos About FAQ Contact Other LinkedIn Reviews All Reviews Leave a Review Rate on Apple Podcasts Rate on Spotify Follow Apple Podcasts Spotify RSS Feed Search Follow Apple Podcasts Spotify RSS Feed Search The Jess Larsen Show on Innovation & Leadership "The Jess Larsen Show on Innovation & Leadership" interviews exciting people and uncommonly hig … & Co-hosted with Holly Parker Building $300M Dream Homes for Billionaires | Grant Bowen, Founder & CEO of Peak Projects Deep Questions with a Navy Seal | Retired Navy SEAL, Diego Ugalde NVIDIA, Taiwan and The Future of AI | Founder and CEO of GMI Cloud, Alex Yeh $8B Success Story to AI Pioneer | Founder, President & CEO of Jivox, Diaz Nesamoney AI evolution in Supply Chains | BlueYonder CEO, Duncan Angove How to Grow Licensing Revenue to $1.5B/yr | Tailscale CEO,
#longevity #agingresearch #innovation #podcast #ericverdin #buckinstitute #juvenescence #cd38 #nad | Rosalba Perrone , Ph.D LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to joi
The Simple Biotech Podcast: ‘Investing in the Longevity Industry: The Greatest Investment Opportunity in Human History’ - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us The Simple Biotech Podcast: ‘Investing in the Longevity Industry: The Greatest Investment Opportunity in Human History’ In the News The Simple Biotech Podcast: ‘Investing in the Longevity Industry: The Greatest Investment Opportunity in Human History’ February 15, 2023 What makes longevity one of the greatest investment opportunities in human history? And what are companies doing to make the future o
JUVENESCENCE Appoints Dr Richard Marshall CBE as CEO - ANSA.it CLOSE_CSS_ALL--> --> --> Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it. Ti invitiamo a leggere le Condizioni Generali di Servizio , la Cookie Policy e l' Informativa Privacy . Accesso Consentless --> ABBONAMENTO CONSENTLESS Puoi leggere tutti i titoli di ANSA.it e 10 contenuti ogni 30 giorni a €16,99/anno Servizio equivalente a quello accessibile prestando il con … Title + ' ' + pageUrl); break; case 'digg': var openLink = 'http://www.digg.com/submit?phase=2&url=' + encodeURIComponent(pageUrl) + '&title=' + encodeURIComponent(pageTitle); break; case 'stumbleupon': var openLink = 'http://www.stumbleupon.com/submit?url=' + encodeURIComponent(pageUrl) + '&title=' + encodeURIComponent(pageTitle); break; case 'delicious': var openLink = 'http://del.icio.us/post?url=' + encodeURIComponent(pageUrl) + '&title=' + encodeURICompon
Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Bus … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership February 26, 2026 | 5 min read Twitter LinkedIn Facebook Email Print PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept tri … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
In the News - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Category: In the News In the News Relation Therapeutics announces $1.7B strategic collaboration with Novartis to advance therapeutics for Atopic Diseases Fantastic news from Relation, announcing a strategic collaboration with Novartis of up to $1.7 billion to discover and advance novel targets for […] In the News Richards interview to Jo Shorthouse 💬 There’s still capital out there – it’s just coming from new directions. Our CEO, Richard Marshall CBE, shares his insights on […] In the News C
UNDERSTANDING (AND TREATING) A… ‑ The Life Sci Fantastic ‑ Apple Podcasts Rechercher Accueil Nouveautés Classements Rechercher 17 octobre 2025 24 min UNDERSTANDING (AND TREATING) AGING The Life Sci Fantastic Lire Across the world, people can now expect to live longer. These advances are thanks to better sanitation, vaccination, access to food and healthcare. But aging inevitably involves decline in many of our biological functions, making people more susceptible to disease. What - if anything - can be done to address the underlying mechanisms of aging to both prevent and treat illness? Can agi
Instagram Instagram Log In Sign Up Close Never miss a post from revivemeexpo Sign up for Instagram to stay in the loop. Sign up Log in revivemeexpo • Follow Original audio More options revivemeexpo Edited • 39w We are pleased to welcome Dr. Richard Marshall, CEO of Juvenescence, as a distinguished speaker at Revive ME. Renowned as a physician scientist and highly experienced executive with a 20-year track record in Pharmaceutical R&D, Dr. Marshall has consistently demonstrated outstanding leadership in developing new medicines to treat diseases of high unmet need. Driven by a passion for i
Longevity for Investors Podcast Home Insights Dr. Bailey's Regimen Podcast About Subscribe Longevity for Investors Podcast The Longevity for Investors podcast mini-series is co-hosted by Dr, Greg Bailey, Chairman of Juvenescence and Jess Larsen. On this series we interview top Longevity experts, CEOs, as well as other interesting High Profile people. Listen on: 43:57 Unlocking Female Longevity: Redefining Menopause as a Choice Dr. Piraye Yurttas Beim, a molecular biologist and entrepreneur, is revolutionizing women's health through her groundbreaking work at... 53:01 Unlocking the Im … europlasticity and rewire it for... 48:14 Insights from Bayer’s $1.5 Billion VC Fund Discover how Bayer's Leaps Venture Capital arm is transforming the biotech landscape by investing in cutting-edge therapies and... 47:35 How Could a New Longevity Medicine Create $200B Per Year in Revenue? What can we learn from an investor who has deployed over $100 million into longevity-focused biotech startups? Alex Colville... 48:38 What This Longevity Investor Knows That You Don&#x
Greg Bailey On Creating $28 Billion In Shareholder Value For His Companies And Now Raising $249 Million To Reverse Aging - Alejandro Cremades Bootstrap CSS --> 🚀 Ready to Raise Capital 3X Faster? Start for Free See How It Works PROGRAMS --> FUNDRAISING TOOLS BLOG DEALMAKERS PODCAST BUSINESS TEMPLATES M&A ADVISOR MY STORY FIND INVESTORS NOW 🧠 Still Guessing What Investors Want? StartupFundraising.com uses AI to show you who’s writing checks—then helps you pitch like a pro and close your round 3× faster. Get Funded Faster → . Greg Bailey On Creating $28 Billion In Shareholder Value For His Com … , Juvenescence, attracted funding from top-tier investors like Longevity Vision Fund, Foresite Capital, Fastforward Innovations, and Grok Ventures. In this episode, you will learn: What Juvenescence is working on Tips for living longer and healthier The advantages of ketosis His top advice when considering launching a business SUBSCRIBE ON: iTunes Google Play Stitcher TuneIn RSS SoundCloud Spotify This episode is brought to you by Gelt. As a referral from the Deal Maker’
Longevity for Investors with Dr. Greg Bailey and Jess Larsen - Podcast - Apple Podcasts Search Home New Top Charts Search Longevity for Investors with Dr. Greg Bailey and Jess Larsen Graystoke Networks 0.0 (0) Investing The Longevity for Investors podcast mini-series is co-hosted by Dr. Greg Bailey, Chairman of Juvenescence https://www.drgregbailey.com/ and Jess Larsen. On this series we interview top Longevity experts, CEOs, as well as other interesting High Profile people. Latest Episode Follow Episodes 01/03/2025 Unlocking Female Longevity: Redefining Menopause as a Choice |
Investing in the Age of Longevity 2024 – Greg Bailey – Juvenescence - YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
News - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us News In the News Juv on the Road Press Releases Publications Videos All Press Releases Juvenescence Completes Phase 1 Trial of PAI-1 Inhibitor February 26, 2026 Press Releases Juvenescence Appoints Eileen Jennings-Brown as CTO and Strengthens UAE Presence in Masdar City’s Life Science Innovation Cluster February 16, 2026 Videos Listen in to the interview to hear our co-founder Dr. Greg Bailey discussing Juvenescence strategy February 5, 2026 Juv on the Road Eric Verdin, our collaborator in the Buck institut
Juvenescence appoints Eileen Jennings-Brown as Chief Technology Officer and strengthens presence in UAE with new partnership and facilities with Masdar City - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Developm … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Juvenescence appoints Eileen Jennings-Brown as Chief Technology Officer and strengthens presence in UAE with new partnership and facilities with Masdar City February 16, 2026 | 5 min read Twitter LinkedIn Facebook Email Print Jennings-Brown will drive AI and technology strategy and lead the development of … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
It's Longevity Week 2020. www.thelongevityforum.com The Longevity Forum are launching a new series of podcasts to discuss the most pressing issues of today and future resilience. A podcast featuring Prof Norman Lazarus will launch on Thursday 12th November. Health is not predetermined and as humans, we can build resilience as explained by Norman Lazarus, Professor at the Centre for Human and Applied Physiological Sciences at Kings College London during his interview with Declan Doogan, Chief Medical Officer of Juvenescence. Release Date: 12 November www.thelongevityforum.com You can subs
Instagram Instagram Log In Sign Up Close Never miss a post from sergeyyoung200 Sign up for Instagram to stay in the loop. Sign up Log in Tags qitone sergeyyoung200 Verified • Follow More options sergeyyoung200 Verified 257w My pick for the Longevity Company of the Month in June is Juvenescence ( @juvlabs ) 🔹Juvenescence is a biotech company that builds a longevity ecosystem and diversified pipeline of therapeutics and technologies. Its business and scientific thesis is that a combination of approaches will be required to tackle aging, and it aims to cover all major areas of aging research 🔹T … se and prevent aging. I am especially excited about ones where Longevity Vision Fund has joined forces with Juvenescence: LyGenesis, a unique organ regeneration platform soon entering human clinical trials, and Insilico Medicine, a leading AI-drug discovery platform that has recently achieved industry first nominating preclinical candidate discovered by AI We look forward to further breakthroughs at Juvenescence and are happy to be working together to extend human healthspans
100 Years of Science with Dr D… - The Longevity Forum's Podcast - Apple Podcasts Search Home New Top Charts Search November 14, 2021 21 min 100 Years of Science with Dr Declan Doogan and James Lovelock The Longevity Forum's Podcast Play Declan Doogan, Chief Medical Officer of Juvenescence, interviews James Lovelock, world-renowned scientist and centenarian on the secret behind the success of his long life. While there appears to be no secret recipe for reaching 100, James discusses the importance of staying active and mentally challenging yourself. As the proposer of the Gaia h
Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi’s M42 alongside strategic partnership - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Jo … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi’s M42 alongside strategic partnership May 21, 2025 | 5 min read Twitter LinkedIn Facebook Email Print Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi’s M42 alongside strategic partnership … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
ADGHW 2025 | Dr Richard Marshall | Juvenescence - YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
Dr Richard Marshall Cbe Md Phd - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Dr Richard Marshall Cbe Md Phd Dr. Richard Marshall, CBE, MD, PhD Chief Executive Officer Dr. Richard Marshall is a physician scientist and a highly experienced executive with a 20-year track record of outstanding leadership in Pharmaceutical R&D. He is driven by a passion for developing new medicines to treat diseases of high unmet need and is excited to lead Juvenescence on its mission to improve the healthspan of people globally. Most recently, Richard was Senior Vice President an
Greg at Founders forum - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Greg at Founders forum Juv on the Road Greg at Founders forum June 30, 2025 Our co-founder, Dr. Greg Bailey, shared key insights on longevity science and the latest exciting developments at Juvenescence® during the Founders Forum Global 20th Anniversary Summit. It was an incredible gathering that addressed many of today’s most pressing topics – thank you to the brilliant minds who joined us in driving these important conversations forward. Grateful to the Founders Forum Group for hosting s
Dr. Gregory Bailey – Juvenescence Italia Skip to content Innovation Team Contact Innovation Team Contact Dr. Grey Bailey Dr. Grey Bailey Chairman Dr. Greg Bailey, MD, a co-founder and the Executive Chairman of Juvenescence, is a physician, financier, and biotech entrepreneur with extensive experience founding and financing healthcare companies. Dr. Bailey is driven by the important opportunity to truly modify aging based on rigorous science. The goal: to use his track record and drug development expertise, and that of his partners, to find compelling products and raise the extraordinary
Longevity Technology: ‘Greg Bailey on Democratizing Healthcare, Paradigm Shifts & Disruptive Technologies’ - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Longevity Technology: ‘Greg Bailey on Democratizing Healthcare, Paradigm Shifts & Disruptive Technologies’ In the News Longevity Technology: ‘Greg Bailey on Democratizing Healthcare, Paradigm Shifts & Disruptive Technologies’ September 26, 2019 Dr. Gregory Bailey, MD , CEO of Juvenescence talks with Longevity Technology to share his thoughts on the longevity field and future plans for Juvenescence.
Listen in to the interview to hear our co-founder Dr. Greg Bailey discussing Juvenescence strategy - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Listen in to the interview to hear our co-founder Dr. Greg Bailey discussing Juvenescence strategy Videos Listen in to the interview to hear our co-founder Dr. Greg Bailey discussing Juvenescence strategy February 5, 2026 Share Tweet Pin It Email Prev Previous New Medicines for the Healthspan Revolution | M42 Join Our Mission to Extend healthspan Contact Us Science Our Approach Team Pipeline News Science Our Approach Tea
Greg Bailey: Biotech can add another 10 healthy years to your life - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Greg Bailey: Biotech can add another 10 healthy years to your life Videos Greg Bailey: Biotech can add another 10 healthy years to your life November 4, 2022 Share Tweet Pin It Email Next Juvenescence: Think aging up, rather than disease down Next Join Our Mission to Extend healthspan Contact Us Science Our Approach Team Pipeline News Science Our Approach Team Pipeline News Subscribe now to stay up to date on news from our team. Subscribe © Juve
Meet @Greg Bailey, M.D, co-founder of Juvenescence® and LEAD’s latest shareholder! As a pioneer in biotech, Dr. Bailey strives for people to live longer, healthier lives, which aligns with LEAD’s… | LEAD LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in
Dr. Greg Bailey | Longevity Home Insights Dr. Bailey's Regimen Podcast About Subscribe Leading the Way in Health and Longevity Welcome to the world of Dr. Greg Bailey, MD, a visionary entrepreneur, renowned thought leader, and leading expert in health and longevity. About Insights Game Changing Portfolio Longevity for Investors Podcast The Longevity for Investors podcast mini-series is co-hosted by Dr. Greg Bailey, Chairman of Juvenescence and Jess Larsen. On this series we interview top Longevity experts, CEOs, as well as other interesting High Profile people. All Episodes Who is Dr. Gre … is not just changing lives; it's changing the world." Brant Panvidic Award-Winning Author, Producer, Director, Public Speaker and Adventurer "Dr. Greg Bailey is an exceptional & influential figure in the realm of optimal aging. His remarkable leadership has spearheaded advancements in anti-aging research, product development, & investment. He is empowering individuals & society to transition from a sickness-focused model towards vibrant aging, offe
Dr Gregory Bailey Md - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Dr Gregory Bailey Md Dr. Greg Bailey, MD Executive Chairman / Co-Founder Dr. Greg Bailey, MD, a co-founder and the Executive Chairman of Juvenescence, is a physician, financier, and biotech entrepreneur with extensive experience founding and financing healthcare companies. Dr. Bailey is driven by the important opportunity to truly modify aging based on rigorous science. The goal: to use his track record and drug development expertise, and that of his partners, to find compelling products and raise
Our CSO, Gill Dines at ARDD Conference - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Our CSO, Gill Dines at ARDD Conference Juv on the Road Our CSO, Gill Dines at ARDD Conference September 30, 2025 Exciting to see such strong global interest in healthspan science at the Aging Research & Drug Discovery Meeting (ARDD) 2025 conference in Copenhagen last week. Our CSO, Gill Dines , joined leading voices from biotech, big pharma, research institutes, policymakers, and academics to discuss how we can translate cutting-edge science into new medicines and insights th
Gill Dines - BioLeader Interview - PIR International Skip to content Search for: Home About Us Executive Search Board Appointments Interims & Fractionals BioLeaders Remuneration & Diversity Studies News Contact Us Search for: NEWS Gill Dines – BioLeader Interview Alex Hope 2026-05-13T07:56:37+00:00 Chief Scientific Offer, Juvenescence (November 2023) Gillian (Gill) Dines is a highly accomplished pharmaceutical executive with 30+ years of experience in research, development, approval, and commercialization of new medicines in both “Big Pharma” and as an entrepreneur in the Biote … een impact on great applicants getting overlooked whilst companies endeavour to apply their diversity agenda. The provision of flexible working and employee wellness support are increasingly important in the retention and attraction of key talent. How are these being managed by your company whilst ensuring that productivity targets are met? I am a firm advocate for flexible working and increasingly I see evolution in the way we work bringing opportunity. Many roles in pharma
Gillian Bio - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Gillian Bio Gillian Dines Chief Science Officer Gillian (Gill) Dines is a highly accomplished pharmaceutical executive with 30+ years of experience in research, development, approval, and commercialization of new medicines in both “Big Pharma” and as an entrepreneur in the Biotech environment. She has led the successful development and global approval of medicines and devices in a number of therapeutic areas including neuroscience, oncology, immunology, respiratory and rare diseases. Before joining Juvenes
Biotech Company - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Innovative medicines to extend healthy lifespan. We extend healthy lifespan through innovative medicines. Our approach centres around developing medicines that target core aging mechanisms to not only treat but prevent age-related diseases. Explore Now Pioneering Prevention for A longer healthspan Reduced chronic disease burden A healthier future Juvenescence is a clinical-stage drug development company dedicated to extending healthy lifespan through innovative medic
Press Releases - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Category: Press Releases Press Releases Juvenescence Completes Phase 1 Trial of PAI-1 Inhibitor Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership PAI-1 Inhibitor (MDI-2517) demonstrates good safety and […] Press Releases Juvenescence Appoints Eileen Jennings-Brown as CTO and Strengthens UAE Presence in Masdar City’s Life Science Innovation Cluster Juvenescence appoints Eileen Jennings-Brown as Chief Technology Offic
Team – Juvenescence Italia Skip to content Innovation Team Contact Innovation Team Contact The Team Dr. Gregory Bailey Chairman Bio Paul Russell CEO Bio Gill Dines CSO/Board Member Bio Eileen Jennings-Brown CTO/ AI Expert Chris Shilling Project Director © 2026, Juvenescence Italia. All rights reserved. Scroll to Top
Juvenescence Completes Phase 1 Trial for PAI-1 Inhibitor MDI-2517 | Juvenescence® posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign i
Juvenescence appoints Eileen Jennings-Brown as CTO | The Pharmaletter Tuesday 2 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardio Vascular
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Yahoo on osa Yahoo-konserni Sivustot ja sovellukset, jotka omistamme ja joita operoimme, mukaan lukien Yahoo ja Engadget, sekä digitaalinen mainospalvelumme (Yahoo Advertising). Yahoo-konsernia . Kun käytät sivustojamme ja sovelluksiamme, käytämme evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä tarjotaksemme sivustomme ja sovelluksemme sinul
Juvenescence Welcomes Eileen Jennings-Brown as CTO, Strengthens Presence in UAE | Juvenescence® posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to … tones and strategic industrial growth. 📌 At a glance: ✔️ Biorce raises €44M to apply artificial intelligence to clinical trials. ✔️ Devicare expands into the US with the acquisition of IP-6 International, Inc. (IP6 Gold® brand). ✔️ Agomab Therapeutics, backed by Asabys Partners , prepares its debut on Nasdaq after raising €300M since 2017. ✔️ IRB Barcelona launches Spain’s first fully integrated Spatial Omics Platform to map biological activity. ✔️ Sistema d’Emergències Mèdi … dustry 4.0 leadership, and founder Jaume Amat receives the Lifetime Achievement Award at La Nit de Catalonia.health . 💡 Curious to explore more? Read the full Picks of February 👉 https://lnkd.in/eJEd-W-i 23 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Portal Biotech Spain 4,882 followers 3mo Report this post Institut d'Investigació i Innovació Parc Taulí (I3PT) participates in MWC and 4YFN to show its potential in biomedical innovation https
Eileen Jennings-Brown - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Eileen Jennings-Brown Eileen Jennings-Brown Chief Technology & Transformation Officer Eileen Jennings-Brown is Chief Technology & Transformation Officer at Juvenescence. She leads the company’s technology strategy and enterprise transformation, with responsibility for building Juvenescence’s AI-enabled drug discovery capability and the digital foundations required to scale globally. Her remit also includes supporting Juvenescence’s regional build-out, putting in place the core capabilitie
Juvenescence Confirms Close of Souvien Therapeutics and Announces High-level Appointments - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Juvenescence Confirms Close of Souvien Therapeutics and Announces High-level Appointments Press Releases Juvenescence Confirms Close of Souvien Therapeutics and Announces High-level Appointments May 28, 2019 Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegenerati
Juvenescence Appoints Dr Richard Marshall CBE as CEO - Juvenescence Science Our Approach Team Pipeline News Contact Us Contact Us Juvenescence Appoints Dr Richard Marshall CBE as CEO Press Releases Juvenescence Appoints Dr Richard Marshall CBE as CEO January 16, 2023 Juvenescence has named Dr Richard Marshall CBE as its new CEO, effective 16 January 2023. Dr Marshall succeeds co-founder Dr Gregory Bailey, who will remain on the company’s board as Executive Chairman. Dr Marshall brings over twenty years of business leadership to the company, with fifteen years at GSK culminating in his position